Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernandez, Carlos, Arasanz, Hugo, Chocarro, Luisa, Bocanegra, Ana, Zuazo, Miren, Fernandez-Hinojal, Gonzalo, Blanco, Ester, Vera, Ruth, Escors, David, Kochan, Grazyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177687/
https://www.ncbi.nlm.nih.gov/pubmed/32244396
http://dx.doi.org/10.3390/ijms21072411

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7177687/
https://www.ncbi.nlm.nih.gov/pubmed/32244396
http://dx.doi.org/10.3390/ijms21072411

Ejemplares similares